Overview

Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
0
Participant gender:
All
Summary
This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
William Rhodes Center for Glioblastoma
Treatments:
Alovudine
Criteria
Inclusion Criteria:

- Male or female ≥ 18 years of age

- Documentation of a suspected HGG diagnosis based on clinical and MRI findings

Exclusion Criteria:

- Pregnant or breastfeeding

- Contraindications to receiving Positron Emission Tomography (PET) imaging (e.g.
claustrophobia)